Northwest Biotherapeutics Inc SEC filings NWBO
Northwest Biotherapeutics Inc has 803 filings in SEC EDGAR's recent list, going back to Aug 13, 2001. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (material agreement, new debt). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Nov 28, 2025 | Dec 29, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 19, 2025 | Dec 29, 2025 |
| DEFA14A | Additional proxy material | Jun 25, 2024 | — |
| DEF 14A | Proxy statement | Jun 3, 2024 | Jun 29, 2024 |
| PRE 14A | Preliminary proxy statement | May 22, 2024 | Jun 29, 2024 |
| DEFA14A | Additional proxy material | Dec 23, 2022 | — |
| DEFA14A | Additional proxy material | Dec 16, 2022 | — |
| DEF 14A | Proxy statement | Dec 5, 2022 | Dec 30, 2022 |
| PRE 14A | Preliminary proxy statement | Nov 25, 2022 | Dec 30, 2022 |
| DEF 14A | Proxy statement | Apr 16, 2021 | May 18, 2021 |
| DEF 14A | Proxy statement | Mar 27, 2020 | Apr 18, 2020 |
| DEF 14A | Proxy statement | Jan 8, 2019 | Feb 2, 2019 |
| DEF 14A | Proxy statement | Apr 9, 2018 | Apr 27, 2018 |
| PRE 14A | Preliminary proxy statement | Mar 26, 2018 | Mar 26, 2018 |
| DEF 14A | Proxy statement | Jan 9, 2018 | Jan 21, 2018 |
| DEF 14A | Proxy statement | Dec 1, 2016 | Dec 22, 2016 |
| DEF 14A | Proxy statement | Nov 6, 2015 | Dec 18, 2015 |
| DEF 14A | Proxy statement | Nov 26, 2014 | Dec 19, 2014 |
| DEF 14A | Proxy statement | Dec 3, 2013 | Dec 20, 2013 |
| DEF 14C | Information statement | Aug 16, 2012 | Aug 21, 2012 |
| PRE 14C | Preliminary information statement | Aug 2, 2012 | Aug 2, 2012 |
| DEF 14C | Information statement | Jan 18, 2012 | Jan 17, 2012 |
| PRE 14C | Preliminary information statement | Dec 16, 2011 | Dec 16, 2011 |
| DEF 14A | Proxy statement | Aug 6, 2009 | Sep 4, 2009 |
| PRE 14A | Preliminary proxy statement | Jul 14, 2009 | Jul 14, 2009 |
| DEF 14A | Proxy statement | May 14, 2008 | Jun 13, 2008 |
| DEF 14C | Information statement | Dec 14, 2007 | Jan 10, 2008 |
| PRE 14C | Schedule 14c | Nov 21, 2007 | Dec 1, 2007 |
| DEF 14C | Information statement | Apr 30, 2007 | May 5, 2007 |
| PRE 14C | Preliminary information statement | Apr 20, 2007 | May 30, 2007 |
| DEF 14C | Information statement | May 1, 2006 | May 25, 2006 |
| PRE 14C | Preliminary information statement | Apr 21, 2006 | May 25, 2006 |
| DEFA14A | Additional proxy material | Dec 2, 2004 | — |
| DEF 14A | Proxy statement | Dec 2, 2004 | Dec 17, 2004 |
| PRE 14A | Preliminary proxy statement | Nov 22, 2004 | Nov 19, 2004 |
| DEF 14A | Proxy statement | Mar 24, 2003 | Apr 24, 2003 |
| DEF 14A | Proxy statement | May 3, 2002 | Jun 20, 2002 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2002 | Jun 20, 2002 |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NWBO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bethesda, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1072379
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.